Pharmacokinetics and pharmacodynamics of antifungal drugs in children

被引：0
作者：
Jullien, V. [1 ]
机构：
[1] Univ Paris 05, Hop St Vincent de Paul, INSERM, Serv Pharmacol Clin,U663, F-75014 Paris, France
来源：
ARCHIVES DE PEDIATRIE | 2011年 / 18卷
关键词：
INVASIVE FUNGAL-INFECTIONS; LIPOSOMAL AMPHOTERICIN-B; POPULATION PHARMACOKINETICS; PEDIATRIC-PATIENTS; PLASMA-CONCENTRATIONS; LIPID COMPLEX; SAFETY; INFANTS; ITRACONAZOLE; VORICONAZOLE;
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
The pharmacokinetics and pharmacodynamics of the main antifungal drugs used for invasive fungal infections (amphotericin B, flucytosine, triazole compounds, echinocandins) have been more or less completely investigated in the paediatric population. This article reviews the pharmacokinetic profiles of these drugs in children, with a focus on the age-related changes. The concentration/efficacy relationships that were evidenced in children are also described. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：S42 / S47
页数：6
相关论文
共 49 条
[1]   Clinical pharmacodynamics of antifungals [J].
Andes, D .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) :635-+
[2]   Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications [J].
Andes, David ;
Pascual, Andres ;
Marchetti, Oscar .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (01) :24-34
[3]   PHARMACOKINETICS, OUTCOME OF TREATMENT, AND TOXIC EFFECTS OF AMPHOTERICIN-B AND 5-FLUOROCYTOSINE IN NEONATES [J].
BALEY, JE ;
MEYERS, C ;
KLIEGMAN, RM ;
JACOBS, MR ;
BLUMER, JL .
JOURNAL OF PEDIATRICS, 1990, 116 (05) :791-797
[4]   Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate [J].
Bekersky, I ;
Fielding, RM ;
Dressler, DE ;
Lee, JW ;
Buell, DN ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :834-840
[5]   Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans [J].
Bekersky, I ;
Fielding, RM ;
Dressler, DE ;
Lee, JW ;
Buell, DN ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :828-833
[6]   Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants [J].
Benjamin, D. K., Jr. ;
Smith, P. B. ;
Arrieta, A. ;
Castro, L. ;
Sanchez, P. J. ;
Kaufman, D. ;
Arnold, L. J. ;
Kovanda, L. L. ;
Sawamoto, T. ;
Buell, D. N. ;
Hope, W. W. ;
Walsh, T. J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (01) :93-99
[7]   Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections [J].
Benjamin, DK ;
Driscoll, T ;
Seibel, NL ;
Gonzalez, CE ;
Roden, MM ;
Kilaru, R ;
Clark, K ;
Dowell, JA ;
Schranz, J ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) :632-638
[8]   PHARMACOKINETICS OF AMPHOTERICIN-B IN CHILDREN [J].
BENSON, JM ;
NAHATA, MC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (11) :1989-1993
[9]   PHARMACOKINETICS OF FLUCONAZOLE IN PEDIATRIC-PATIENTS [J].
BRAMMER, KW ;
COATES, PE .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1994, 13 (04) :325-329
[10]  
CLEMENTS JS, 1990, AM J MED, V88, pN22
12345